Spectral AI Schedules 2024 Third Quarter Financial Results and Conference Call
Spectral AI (Nasdaq: MDAI), an AI company specializing in medical diagnostics for wound care, has announced its upcoming Q3 2024 financial results release. The results will be disclosed on November 6, 2024, after market close, followed by a conference call at 5:00 pm Eastern Time. Investors can participate via phone (U.S.: 833-630-1956, International: 412-317-1837) or access the webcast through the company's investor relations website.
Spectral AI (Nasdaq: MDAI), un'azienda di intelligenza artificiale specializzata nella diagnostica medica per la cura delle ferite, ha annunciato il rilascio dei suoi prossimi risultati finanziari del Q3 2024. I risultati saranno resi noti il 6 novembre 2024, dopo la chiusura del mercato, seguiti da una teleconferenza alle 17:00 ora orientale. Gli investitori possono partecipare tramite telefono (U.S.: 833-630-1956, Internazionale: 412-317-1837) o accedere alla webcast tramite il sito web delle relazioni con gli investitori dell'azienda.
Spectral AI (Nasdaq: MDAI), una empresa de IA especializada en diagnósticos médicos para el cuidado de heridas, ha anunciado la próxima publicación de sus resultados financieros del Q3 2024. Los resultados se darán a conocer el 6 de noviembre de 2024, después del cierre del mercado, seguidos de una llamada de conferencia a las 5:00 pm, hora del Este. Los inversores pueden participar por teléfono (EE. UU.: 833-630-1956, Internacional: 412-317-1837) o acceder a la transmisión a través del sitio web de relaciones con inversionistas de la empresa.
스펙트럴 AI (Nasdaq: MDAI), 상처 치료를 위한 의료 진단에 특화된 AI 회사가 2024년 3분기 재무 결과 발표를 예정하고 있습니다. 결과는 2024년 11월 6일 시장이 마감된 후 발표되며, 오후 5시 동부 표준시부터 컨퍼런스 콜이 진행됩니다. 투자자들은 전화(미국: 833-630-1956, 국제: 412-317-1837)를 통해 참여하거나 회사의 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있습니다.
Spectral AI (Nasdaq: MDAI), une entreprise d'IA spécialisée dans le diagnostic médical pour les soins des plaies, a annoncé la prochaine publication de ses résultats financiers du T3 2024. Les résultats seront divulgués le 6 novembre 2024, après la clôture des marchés, suivis d'une conférence téléphonique à 17h00, heure de l'Est. Les investisseurs peuvent participer par téléphone (É.-U.: 833-630-1956, International: 412-317-1837) ou accéder au webinaire via le site web des relations avec les investisseurs de l'entreprise.
Spectral AI (Nasdaq: MDAI), ein KI-Unternehmen, das sich auf medizinische Diagnostik für die Wundversorgung spezialisiert hat, hat die bevorstehende Veröffentlichung der Q3 2024 Finanzberichte angekündigt. Die Ergebnisse werden am 6. November 2024, nach Börsenschluss veröffentlicht, gefolgt von einer Telefonkonferenz um 17:00 Uhr Eastern Time. Investoren können per Telefon (USA: 833-630-1956, International: 412-317-1837) teilnehmen oder über die Investor-Relations-Website des Unternehmens auf das Webcast zugreifen.
- None.
- None.
DALLAS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the third quarter ended September 30, 2024 on Wednesday, November 6, 2024 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results.
Investors interested in participating in the live call can dial:
- 833-630-1956 - U.S.
- 412-317-1837 - International
A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Investors:
The Equity Group
Devin Sullivan
Managing Director
dsullivan@equityny.com
Conor Rodriguez
Analyst
crodriguez@equityny.com
FAQ
When will Spectral AI (MDAI) release its Q3 2024 earnings?
How can investors join Spectral AI's (MDAI) Q3 2024 earnings call?
What time is Spectral AI's (MDAI) Q3 2024 earnings conference call?
